Inter Pharma PCL

Inter Pharma maintains a conservative capital structure with a debt-to-equity ratio of 0.19, significantly below the median for the Pharmaceuticals industry, indicating limited leverage risk. The company’s liquidity position is mixed, with a current ratio of 1.73 but negative net cash after subtracting total debt, signaling potential short-term liquidity constraints. Free cash flow of 88.9 million THB supports operational flexibility, though capital expenditures of -163.7 million THB suggest asset disposals or reduced investment in the period. Profitability metrics show a return on equity of 5.94% and return on assets of 3.78%, both below the industry median for Pharmaceuticals, which typically exceeds 8% ROE and 5% ROA. This underperformance may reflect competitive pressures or margin compression in its core markets. The company’s revenue is distributed across three segments: Human healthcare, Animal healthcare, and Hospital and clinics. While disclosed revenue by segment is not available, the product portfolio suggests a diversified approach, with offerings in pharmaceuticals, nutraceuticals, and pet care. Geographically, the company is concentrated in Thailand, with no material international revenue disclosed, exposing it to local economic and regulatory risks. Growth trajectory remains uncertain, as no forward-looking revenue deltas are provided in the outlook. Historical revenue of 2.19 billion THB indicates stable operations but lacks evidence of expansion. The absence of capital expenditure growth and limited free cash flow reinvestment may constrain long-term growth. Risk factors include medium liquidity risk due to negative net cash and a low dilution risk score. No dilution sources are identified in the risk assessment, and no adjustments are applied in custom valuations, suggesting no recent equity issuance or share buybacks. Recent events include no disclosed filings or transcripts in the input data, limiting visibility into management commentary or strategic shifts. The company’s focus on biotechnology for disease prevention and anti-aging remains a key differentiator but is not yet reflected in financial outperformance.